System; Lupus ErythematosusTIR-CURNCT07398885
Assessing the Impact of Herbal Supplement on Fatigue and Disease Activity in SLE: Results From an 8-Week Randomized Trial
A study testing EVACUR in people with System; Lupus Erythematosus, run by University Tunis El Manar at 1 site in Tunisia.
Trial summary
Fatigue is one of the most prevalent and disabling manifestations of systemic lupus erythematosus. Although its management often entails a combination of pharmacologic and non-pharmacologic strategies, no pharmacologic intervention has yet demonstrated consistent efficacy. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- System; Lupus Erythematosus
- What is being tested?
- EVACUR
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 59 participants
- Where
- 1 siteTunisia
- Study dates
- 1 Jul 2024to 7 May 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age > 18 years
- Confirmed diagnosis of SLE according to the 2019 ACR/EULAR classification criteria
- Presence of fatigue, defined as a FACIT-F score < 34
- Signed informed consent
- Non-Inclusion Criteria:
- Pregnancy or breastfeeding
Show all 9Show fewer
- Diseases or comorbidities that may influence fatigue:untreated hypothyroidism, psychosis common infections, and other autoimmune and inflammatory diseases
- Patients on vitamin K antagonist therapy, due to a possible interaction with Ginger and Nigella
- History of severe allergy or intolerance to EVACUR or any component of the placebo
Who cannot join
- Diagnosis of another systemic disease during the study period
- Pregnancy
- Allergy to any component of EVACUR
- Withdrawal of consent
Trial locations and contacts
1 site in 1 country.
About this study
Fatigue is one of the most prevalent and disabling manifestations of systemic lupus erythematosus. Although its management often entails a combination of pharmacologic and non-pharmacologic strategies, no pharmacologic intervention has yet demonstrated consistent efficacy.
Aim: The purpose of this clinical study was to explore the efficacy of using herbal-based treatment on patients with SLE-related fatigue .
Methods: We performed a 8-week,randomized, double-blinded, placebo-controlled clinical trial in two internal medicine departments in Tunisia over a period of 2 months. We included patients with SLE who met the classification criteria of the 2019-EULAR/ACR classification criteria for SLE and had a FACIT-F (Functional Assessment of Chronic Illness Therapy-fatigue) score minor than 34. After screening, patients were randomly assigned to the EVACUR treatment group or placebo group. The primary endpoints were changes in fatigue (FACIT-F) and disease activity (SLEDAI) scores.
Read the detailed description
Study Type:
This was a randomized, double-blind clinical trial conducted in two internal medicine departments in Tunisia over a period of 3 months.
Study Population:
Patients with a diagnosis of SLE who were being followed in the participating departments.
Inclusion Criteria:
Age superior than 18 years Confirmed diagnosis of SLE according to the 2019 ACR/EULAR classification criteria Presence of fatigue, defined as a FACIT-F score < 34 Signed informed consent
Non-Inclusion Criteria:
Pregnancy or breastfeeding Diseases or comorbidities that may influence fatigue:untreated hypothyroidism, psychosis common infections, and other autoimmune and inflammatory diseases Patients on vitamin K antagonist therapy, due to a possible interaction with Ginger and Nigella History of severe allergy or intolerance to EVACUR or any component of the placebo
Exclusion Criteria:
Diagnosis of another systemic disease during the study period Pregnancy Allergy to any component of EVACUR Withdrawal of consent
Data Collection:
Patient data were collected from medical records,including epidemiological characteristics such as age at inclusion , gender and medical and family history .Disease-specific data included the duration disease, systemic manifestations,nature of treatement at inclusion .Disease activity was evaluated using clinical SLEDAI-2K score. Baseline FACIT score was collected.Biological assessments were performed such us Anti-dsDNA antibody titers ,ANA and serum C3 and C4 levels.
Study protocol:
Randomization:
A two -to-one (2:1) randomization was performed in this study in which patients were randomly assigned into two groups: Group 1 (G1) which received EVACUR, and Group 2 (G2) received a placebo. Randomization was handled by an independent third party using a dedicated randomization software.
Double-Blind Design:
Neither the patients nor the investigators knew the treatment assignment. EVACUR and placebo capsules are identical in appearance.
Treatement:
EVACUR:
A phytotherapeutic compound presented in capsule form. Each bottle contains 40 capsules composed of: Nigella seed, Zinc sulfate, Echinacea, Vitamin C, Red ginseng, Ginger, Chamomile, Spirulina, Royal jelly, Ganoderma, Vitamins B1, B6, B12, Selenium(Table1).
Contra-indications: Allergy to any component of the supplement. Table 1. Ingredients and Dosage of EVACUR Formulation per Capsule Ingredient Latin/INCI Name Form/Quality Quantity per capsule Black seed Nigella sativa Dry extract 80 mg Echinacea Echinacea spp. Dry extract 40 mg Ginger Zingiber officinale Dry extract 30 mg Chamomile Matricaria chamomilla Dry extract 10 mg Red ginseng Panax ginseng Dry extract 10 mg Reishi mushroom Ganoderma lucidum Dry extract 10 mg Spirulina Spirulina spp. Dry extract 60 mg Royal jelly Royal jelly Lyophilized 20 mg Vitamin C Ascorbic acid - 30 mg Zinc Zinc sulfate - 2.5 mg Vitamin B1 Thiamine - 3 mg Vitamin B6 Pyridoxine Marine source 4 mg Vitamin B12 Cobalamin - 10 µg Selenium Selenium yeast - 40 µg
Placebo:
Capsules containing starch, packaged identically to EVACUR bottles. Both treatments will be administered at a dose of 2 capsules per day in the morning (3 bottles per patient for the study duration).
Follow-up:
Patients attended three visits at baselineM0, one monthM1, and two monthsM2. The FACIT score was assessed during each visit along with a physical examination.
Adverse Events:
Potential side effects will be recorded and evaluated throughout the study. Occurrence of any adverse event will lead to patient exclusion and trigger a pharmacovigilance investigation. All adverse events must be reported immediately to the principal investigator.
Fatigue Assessment Score:
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) A 13-item questionnaire with responses on a Likert scale from 1 (not at all) to 5 (very much).
Total score out of 52; higher scores indicate less fatigue.Can be calculated if at least 50% of the questions are answered.
Reliability: High (Cronbach's alpha = 0.94) Validity: Strong, with good correlation with other fatigue measurement tools Completion time: 5-10 minutes A validated Arabic version is available with good psychometric properties .
Evaluation Criteria:
Primary Endpoint:
A mean Facit-F score improvement between G1 and G2 at month2 > Minimal Clinically Important Difference(MCID).The MCID in SLE is estimated at 3.4T[5].
Secondary Endpoints:
Improvement in the disease activity SLEDAI score Good tolerance of the dietary supplement.
Statistical Analysis:
Data were analyzed using SPSS.Appropriate statistical tests will be applied, including Student's t-test or the Wilcoxon test.Randomization will be conducted using dedicated software.
- Conditions
- System; Lupus Erythematosus
- Being tested
- EVACUR, PLACEBO
- Keywords
- Systemic Lupus Erythematosus , Fatigue, EVACUR, Herbal supplement, FACIT-F, SLEDAI, Randomized controlled trial.
- Medical subject headings
- Lupus Erythematosus, Systemic, Fatigue
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EVACURDietary supplement
It is a herbal therapy in capsule form. It is a bottle containing 40 capsules composed of: black seed, zinc sulfate, Echinacea, vitamin C, red ginseng, ginger, chamomile, spirulina, royal jelly, Ganoderma, vitamin B1, B6, B12, selenium.
EVACUR is adminstrated at a rate of 2 capsules per day in the morning
PLACEBOOther
starch capsules arranged in a bottle that looks identical to that of EVACUR. It is administered at a rate of 2 capsules per day in the morning.
| Study group | Role | What they receive |
|---|---|---|
| EVACUR | Experimental | EVACUR and the placebo are produced by the Wellnet laboratory. It is a herbal therapy in capsule form. It is a bottle containing 40 capsules composed of: black seed, zinc sulfate, Echinacea, vitamin C, red ginseng, ginger, chamomile, spirulina, royal jelly, Ganoderma, vitamin B1, B6, B12, selenium.
Ingredient Latin/INCI Name Form/Quality Quantity per capsule Black seed Nigella sativa Dry extract 80 mg Echinacea Echinacea spp. Dry extract 40 mg Ginger Zingiber officinale Dry extract 30 mg Chamomile Matricaria chamomilla Dry extract 10 mg Red ginseng Panax ginseng Dry extract 10 mg Reishi mushroom Ganoderma lucidum Dry extract 10 mg Spirulina Spirulina spp. Dry extract 60 mg Royal jelly Royal jelly Lyophilized 20 mg Vitamin C Ascorbic acid - 30 mg Zinc Zinc sulfate - 2.5 mg Vitamin B1 Thiamine - 3 mg Vitamin B6 Pyridoxine Marine source 4 mg Vitamin B12 Cobalamin - 10 µg Selenium Selenium yeast - 40 µg Receives: Dietary Supplement: EVACUR |
| PLACEBO | Placebo comparator | consists of starch capsules arranged in a bottle that looks identical to that of EVACUR. Receives: Other: PLACEBO |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tirderness Score: Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
- This is a 13-question questionnaire to which the patient responds on a Likert scale ranging from 1 to 5 (1 = completely, 5 = not at all). By adding up the responses, a score out of 65 is obtained. The higher the score, the less fatigued the patient is [2].
- The score can be calculated once the patient has answered 50% of the questions.
- Reliability: The Cronbach's alpha is good (0.94).
- Validity: This tool has good validity as it has a strong correlation with the use of other scales.
- It takes 5 to 10 minutes to complete the questionnaire and calculate the score.
- The Arabic version (Appendix 3) has been validated with good psychometric properties
Measured: at inclusion, after 1, 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Feb 2026
- Study start1 Jul 2024
- Primary completion1 Apr 2025
- Study completion7 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for System; Lupus ErythematosusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized double-blind clinical trial conducted at various internal medicine services in Tunisia over a period of 3 months.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 59 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Tunis El Manar
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tayssir Ben Achour, University Tunis El Manar
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07398885
- Sponsor's protocol ID
- UTelmanar
- Acronym
- TIR-CUR
- Status last verified
- Sep 2025
- First submitted
- 13 Mar 2024
- Last updated
- 10 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005 May;32(5):811-9.
PubMed 15868614Al Maqbali M, Hughes C, Gracey J, Rankin J, Hacker E, Dunwoody L. Psychometric Properties of the Arabic Version of the Functional Assessment of Chronic Illnesses Therapy-Fatigue in Arabic Cancer Patients. J Pain Symptom Manage. 2020 Jan;59(1):130-138.e2. doi: 10.1016/j.jpainsymman.2019.10.008. Epub 2019 Oct 21.
PubMed 31647976Dey M, Parodis I, Nikiphorou E. Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management. J Clin Med. 2021 Aug 13;10(16):3566. doi: 10.3390/jcm10163566.
PubMed 34441861Mertz P, Schlencker A, Schneider M, Gavand PE, Martin T, Arnaud L. Towards a practical management of fatigue in systemic lupus erythematosus. Lupus Sci Med. 2020 Nov;7(1):e000441. doi: 10.1136/lupus-2020-000441.
PubMed 33214160
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessing the Impact of Herbal Supplement on Fatigue and Disease Activity in SLE: Results From an 8-Week Randomized Trial
- ClinicalTrials.gov ID
- NCT07398885
- Acronym / sponsor ID
- TIR-CUR / UTelmanar
- Conditions
- System; Lupus Erythematosus
- Keywords
- Systemic Lupus Erythematosus , Fatigue, EVACUR, Herbal supplement, FACIT-F, SLEDAI, Randomized controlled trial.
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 59 participants (actual)
- Lead sponsor
- University Tunis El ManarUniversity, hospital or other
- Study start
- 1 Jul 2024 (actual)
- Primary completion
- 1 Apr 2025 (actual)
- Study completion
- 7 May 2025 (actual)
- First posted
- 10 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Fatigue is one of the most prevalent and disabling manifestations of systemic lupus erythematosus. Although its management often entails a combination of pharmacologic and non-pharmacologic strategies, no pharmacologic intervention has yet demonstrated consistent efficacy.
Aim: The purpose of this clinical study was to explore the efficacy of using herbal-based treatment on patients with SLE-related fatigue .
Methods: We performed a 8-week,randomized, double-blinded, placebo-controlled clinical trial in two internal medicine departments in Tunisia over a period of 2 months. We included patients with SLE who met the classification criteria of the 2019-EULAR/ACR classification criteria for SLE and had a FACIT-F (Functional Assessment of Chronic Illness Therapy-fatigue) score minor than 34. After screening, patients were randomly assigned to the EVACUR treatment group or placebo group. The primary endpoints were changes in fatigue (FACIT-F) and disease activity (SLEDAI) scores.
Detailed description
Study Type:
This was a randomized, double-blind clinical trial conducted in two internal medicine departments in Tunisia over a period of 3 months.
Study Population:
Patients with a diagnosis of SLE who were being followed in the participating departments.
Inclusion Criteria:
Age superior than 18 years Confirmed diagnosis of SLE according to the 2019 ACR/EULAR classification criteria Presence of fatigue, defined as a FACIT-F score < 34 Signed informed consent
Non-Inclusion Criteria:
Pregnancy or breastfeeding Diseases or comorbidities that may influence fatigue:untreated hypothyroidism, psychosis common infections, and other autoimmune and inflammatory diseases Patients on vitamin K antagonist therapy, due to a possible interaction with Ginger and Nigella History of severe allergy or intolerance to EVACUR or any component of the placebo
Exclusion Criteria:
Diagnosis of another systemic disease during the study period Pregnancy Allergy to any component of EVACUR Withdrawal of consent
Data Collection:
Patient data were collected from medical records,including epidemiological characteristics such as age at inclusion , gender and medical and family history .Disease-specific data included the duration disease, systemic manifestations,nature of treatement at inclusion .Disease activity was evaluated using clinical SLEDAI-2K score. Baseline FACIT score was collected.Biological assessments were performed such us Anti-dsDNA antibody titers ,ANA and serum C3 and C4 levels.
Study protocol:
Randomization:
A two -to-one (2:1) randomization was performed in this study in which patients were randomly assigned into two groups: Group 1 (G1) which received EVACUR, and Group 2 (G2) received a placebo. Randomization was handled by an independent third party using a dedicated randomization software.
Double-Blind Design:
Neither the patients nor the investigators knew the treatment assignment. EVACUR and placebo capsules are identical in appearance.
Treatement:
EVACUR:
A phytotherapeutic compound presented in capsule form. Each bottle contains 40 capsules composed of: Nigella seed, Zinc sulfate, Echinacea, Vitamin C, Red ginseng, Ginger, Chamomile, Spirulina, Royal jelly, Ganoderma, Vitamins B1, B6, B12, Selenium(Table1).
Contra-indications: Allergy to any component of the supplement. Table 1. Ingredients and Dosage of EVACUR Formulation per Capsule Ingredient Latin/INCI Name Form/Quality Quantity per capsule Black seed Nigella sativa Dry extract 80 mg Echinacea Echinacea spp. Dry extract 40 mg Ginger Zingiber officinale Dry extract 30 mg Chamomile Matricaria chamomilla Dry extract 10 mg Red ginseng Panax ginseng Dry extract 10 mg Reishi mushroom Ganoderma lucidum Dry extract 10 mg Spirulina Spirulina spp. Dry extract 60 mg Royal jelly Royal jelly Lyophilized 20 mg Vitamin C Ascorbic acid - 30 mg Zinc Zinc sulfate - 2.5 mg Vitamin B1 Thiamine - 3 mg Vitamin B6 Pyridoxine Marine source 4 mg Vitamin B12 Cobalamin - 10 µg Selenium Selenium yeast - 40 µg
Placebo:
Capsules containing starch, packaged identically to EVACUR bottles. Both treatments will be administered at a dose of 2 capsules per day in the morning (3 bottles per patient for the study duration).
Follow-up:
Patients attended three visits at baselineM0, one monthM1, and two monthsM2. The FACIT score was assessed during each visit along with a physical examination.
Adverse Events:
Potential side effects will be recorded and evaluated throughout the study. Occurrence of any adverse event will lead to patient exclusion and trigger a pharmacovigilance investigation. All adverse events must be reported immediately to the principal investigator.
Fatigue Assessment Score:
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) A 13-item questionnaire with responses on a Likert scale from 1 (not at all) to 5 (very much).
Total score out of 52; higher scores indicate less fatigue.Can be calculated if at least 50% of the questions are answered.
Reliability: High (Cronbach's alpha = 0.94) Validity: Strong, with good correlation with other fatigue measurement tools Completion time: 5-10 minutes A validated Arabic version is available with good psychometric properties .
Evaluation Criteria:
Primary Endpoint:
A mean Facit-F score improvement between G1 and G2 at month2 > Minimal Clinically Important Difference(MCID).The MCID in SLE is estimated at 3.4T[5].
Secondary Endpoints:
Improvement in the disease activity SLEDAI score Good tolerance of the dietary supplement.
Statistical Analysis:
Data were analyzed using SPSS.Appropriate statistical tests will be applied, including Student's t-test or the Wilcoxon test.Randomization will be conducted using dedicated software.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomized double-blind clinical trial conducted at various internal medicine services in Tunisia over a period of 3 months.
| Arm | Type | Receives |
|---|---|---|
| EVACUR | Experimental | Dietary Supplement: EVACUREVACUR and the placebo are produced by the Wellnet laboratory. It is a herbal therapy in capsule form. It is a bottle containing 40 capsules composed of: black seed, zinc sulfate, Echinacea, vitamin C, red ginseng, ginger, chamomile, spirulina, royal jelly, Ganoderma, vitamin B1, B6, B12, selenium. Ingredient Latin/INCI Name Form/Quality Quantity per capsule Black seed Nigella sativa Dry extract 80 mg Echinacea Echinacea spp. Dry extract 40 mg Ginger Zingiber officinale Dry extract 30 mg Chamomile Matricaria chamomilla Dry extract 10 mg Red ginseng Panax ginseng Dry extract 10 mg Reishi mushroom Ganoderma lucidum Dry extract 10 mg Spirulina Spirulina spp. Dry extract 60 mg Royal jelly Royal jelly Lyophilized 20 mg Vitamin C Ascorbic acid - 30 mg Zinc Zinc sulfate - 2.5 mg Vitamin B1 Thiamine - 3 mg Vitamin B6 Pyridoxine Marine source 4 mg Vitamin B12 Cobalamin - 10 µg Selenium Selenium yeast - 40 µg |
| PLACEBO | Placebo comparator | Other: PLACEBOconsists of starch capsules arranged in a bottle that looks identical to that of EVACUR. |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Age > 18 years
- Confirmed diagnosis of SLE according to the 2019 ACR/EULAR classification criteria
- Presence of fatigue, defined as a FACIT-F score < 34
- Signed informed consent
- Pregnancy or breastfeeding
Key exclusion criteria (4 listed)
- Diagnosis of another systemic disease during the study period
- Pregnancy
- Allergy to any component of EVACUR
- Withdrawal of consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EVACURIt is a herbal therapy in capsule form. It is a bottle containing 40 capsules composed of: black seed, zinc sulfate, Echinacea, vitamin C, red ginseng, ginger, chamomile, spirulina, royal jelly, Ganoderma, vitamin B1, B6, B12, selenium. EVACUR is adminstrated at a rate of 2 capsules per day in the morning | Dietary supplement | EVACUR |
| PLACEBOstarch capsules arranged in a bottle that looks identical to that of EVACUR. It is administered at a rate of 2 capsules per day in the morning. | Other | PLACEBO |
Primary outcome
Tirderness Score: Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
Time frame: at inclusion, after 1, 2 months
* This is a 13-question questionnaire to which the patient responds on a Likert scale ranging from 1 to 5 (1 = completely, 5 = not at all). By adding up the responses, a score out of 65 is obtained. The higher the score, the less fatigued the patient is [2]. * The score can be calculated once the patient has answered 50% of the questions. * Reliability: The Cronbach's alpha is good (0.94). * Validity: This tool has good validity as it has a strong correlation with the use of other scales. * It takes 5 to 10 minutes to complete the questionnaire and calculate the score. * The Arabic version (Appendix 3) has been validated with good psychometric properties
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2026.
- Background: PubMed 15868614Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005 May;32(5):811-9.
- Background: PubMed 31647976Al Maqbali M, Hughes C, Gracey J, Rankin J, Hacker E, Dunwoody L. Psychometric Properties of the Arabic Version of the Functional Assessment of Chronic Illnesses Therapy-Fatigue in Arabic Cancer Patients. J Pain Symptom Manage. 2020 Jan;59(1):130-138.e2. doi: 10.1016/j.jpainsymman.2019.10.008. Epub 2019 Oct 21.
- Results publication: PubMed 34441861Dey M, Parodis I, Nikiphorou E. Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management. J Clin Med. 2021 Aug 13;10(16):3566. doi: 10.3390/jcm10163566.
- Results publication: PubMed 33214160Mertz P, Schlencker A, Schneider M, Gavand PE, Martin T, Arnaud L. Towards a practical management of fatigue in systemic lupus erythematosus. Lupus Sci Med. 2020 Nov;7(1):e000441. doi: 10.1136/lupus-2020-000441.
- Individual participant dataSharing planned: No
Related trials for System; Lupus Erythematosus
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
RecruitingPhase 4
Dapagliflozin in Active Lupus Nephritis
Lupus Nephritis (LN)
RecruitingObservational study
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
RecruitingObservational study
Deciphering the Genetic Architecture of Autoimmune Diseases
Autoimmune Diseases
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing EVACUR in people with System; Lupus Erythematosus, run by University Tunis El Manar at 1 site in Tunisia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Tunisia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tirderness Score: Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) (time frame: at inclusion, after 1, 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07398885, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2026.